Bio-Rad Laboratories (BIO) News Today

UniSuper Management Pty Ltd lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 585.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,865 shares of the medical research company's stock

Bio-Rad Laboratories (NYSE:BIO) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=609808)

Seven Eight Capital LP boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 69.1% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 4,824 shares of the medical research company's stock after buying an additional 1,972 shares durin

StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Monday.

Acadian Asset Management LLC decreased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 28.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,064 shares of the medical research company'

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 10.2% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,850 shares of the medical research company

Entropy Technologies LP cut its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 35.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,845 shares of the medical research company's s

Qsemble Capital Management LP purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,639 shares of the medical research compan

Swiss National Bank decreased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 4.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 64,900 shares of the medical research company's stock after selling 2,700 s

Sei Investments Co. boosted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 18.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 186,626 shares of the medical res

Duality Advisers LP reduced its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 85.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,258 shares of the medical research company's stock after selling 7,306 sh

Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,280,000 shares, a growth of 47.6% from the June 15th total of 867,500 shares. Currently, 6.5% of the shares of the company are short sold. Based on an average trading volume of 249,800 shares, the days-to-cover ratio is currently 5.1 days.

StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Friday.

Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on

DAVENPORT & Co LLC bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 44,353 shares of the medical research company's stock, valued at approximately $15,340,000. DAVENPORT & Co

Easterly Investment Partners LLC reduced its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 93.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,060 shares of the medical research company'

Capstone Investment Advisors LLC reduced its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 77.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,293 shares of the medical research company's s

Diversified Trust Co lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 259.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,957 shares of the medic

Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 867,500 shares, a growth of 15.3% from the May 31st total of 752,200 shares. Based on an average trading volume of 241,100 shares, the days-to-cover ratio is presently 3.6 days. Approximately 4.4% of the company's shares are sold short.

Vanguard Group Inc. lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 2.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,389,889 shares of the med

Goldman Sachs Group Inc. grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 454.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 144,333 shares of the medical research company's stock after buying an add

Quadrature Capital Ltd increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 87.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,820 shares of the medical research company's stock after purcha

Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issu

Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) EVP Michael Crowley sold 369 shares of the business's stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $281.91, for a total transaction of $104,024.79. Following the completion of the transaction, the executive vice president now owns 6,573 shares of the company's stock, valued at approximately $1,852,994.43. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Prelude Capital Management LLC boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 21.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 49,549 shares of the medica

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities researchers at Zacks Research decreased their Q2 2025 earnings estimates for shares of Bio-Rad Laboratories in a research report issued to clients and investors on Tuesday, June 11th. Zacks Research analyst R. Anand now forecasts that

Point72 Hong Kong Ltd bought a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 22,517 shares of the medical research company's stock, valu

Point72 Europe London LLP bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 39,449 shares of the medical research company's stock, valued

Bellevue Group AG increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 5.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 141,147 shares of the medical research company's stock after acquiring an additi

The Manufacturers Life Insurance Company raised its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 303.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,610 shares of t

Quadrature Capital Ltd increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 87.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,820 shares of the medical research company's stock

CIBC Private Wealth Group LLC bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 43,287 shares of the medical research

Eisler Capital UK Ltd. acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,132 shares of the medical research company's st

Campbell & CO Investment Adviser LLC purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 8,080 shares of the medical research company's s

Jefferies Financial Group reaffirmed a "hold" rating and set a $315.00 price target (down previously from $440.00) on shares of Bio-Rad Laboratories in a research note on Monday.

UBS Group AG decreased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 11.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,496 shares of the medical research company's stock afte

Franklin Resources Inc. cut its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 27.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,000 shares of the medical research company's stock after selling 7,3

Parnassus Investments LLC boosted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 7.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 237,790 shares of the medical research company's stock after a

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities research analysts at Zacks Research boosted their Q2 2025 EPS estimates for Bio-Rad Laboratories in a note issued to investors on Tuesday, May 28th. Zacks Research analyst R. Anand now expects that the medical research company will po

First Pacific Advisors LP acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 4,866 shares of the medical research company's stock, valued at approximately

StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Tuesday.

Norges Bank purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 226,523 shares of the medical research company's stock, va

Westfield Capital Management Co. LP lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 31.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 247,210 shares of the medical research company